NVO - Roivant Sciences benefits from Arbutus patent win over Moderna; shares up 37%

Shares of Roivant Sciences (ROIV +33.8%) are surging thanks to Arbutus Biopharma's (ABUS +68.0%) patent dispute win over Moderna (MRNA -7.7%). As of last month, Roivant owns 29.1% of Arbutus common shares. Roivant made a $116M strategic investment in Arbutus in October 2017. Seeking Alpha contributor Terry Chrisomalis says that Arbutus could be a takeover target given its RNAi candidates and Novo Nordisk's (NVO +1.5%) recent $3B acquisition of RNAi drugmaker Dicerna (DRNA +0.4%).

For further details see:

Roivant Sciences benefits from Arbutus patent win over Moderna; shares up 37%